Arrowhead Pharmaceuticals (ARWR) Quick Ratio: History & Chart

Arrowhead Pharmaceuticals, Inc.(ARWR)

Biotechnology · Pasadena, CA

$62.35-1.84 (-2.87%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Pasadena, CA

711 employees

arrowheadpharma.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Christopher R. Anzalone

View full financials

ARWR Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

5.90

QUICK RATIO (ACID-TEST) AVG TTM

5.05

QUICK RATIO (ACID-TEST) AVG 3Y

5.42

QUICK RATIO (ACID-TEST) AVG 5Y

4.69

QUICK RATIO (ACID-TEST) AVG 10Y

4.71

QUICK RATIO (ACID-TEST) AVG 15Y

4.73

QUICK RATIO (ACID-TEST) AVG 20Y

4.86

CURRENT VS TTM AVG

+16.85%

CURRENT VS 3Y AVG

+8.86%

CURRENT VS 5Y AVG

+25.75%

CURRENT VS 10Y AVG

+25.29%

CURRENT VS 15Y AVG

+24.82%

CURRENT VS 20Y AVG

+21.27%

SECTOR MEDIAN · HEALTHCARE

2.85

median of 440 covered companies

CURRENT VS SECTOR MEDIAN

+106.98%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Arrowhead Pharmaceuticals, Inc. (ARWR)	$8.78B	5.90	5.05	5.42	4.69
Caris Life Sciences, Inc. (CAI)vs ›	$8.59B	4.88	4.46	3.60	3.01
Axsome Therapeutics, Inc. (AXSM)vs ›	$9.11B	1.34	1.76	2.38	3.52
Oscar Health, Inc. (OSCR)vs ›	$8.41B	1.08	0.93	1.08	1.24
Bruker Corporation (BRKRP)vs ›	$9.35B	0.92	0.82	1.02	1.25
Insulet Corp. (PODD)vs ›	$9.39B	1.83	2.42	2.51	3.28
Henry Schein, Inc. (HSIC)vs ›	$9.60B	0.73	0.77	0.86	0.88
Bruker Corporation (BRKR)vs ›	$9.72B	0.92	0.82	1.02	1.25
Cytokinetics, Incorporated (CYTK)vs ›	$7.80B	6.66	5.35	6.55	8.14
HealthEquity, Inc. (HQY)vs ›	$7.65B	2.99	3.17	3.50	3.09

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Arrowhead Pharmaceuticals, Inc. (ARWR)

$8.78B

5.90

5.05

5.42

4.69

Caris Life Sciences, Inc. (CAI)vs ›

$8.59B

4.88

4.46

3.60

3.01

Axsome Therapeutics, Inc. (AXSM)vs ›

$9.11B

1.34

1.76

2.38

3.52

Oscar Health, Inc. (OSCR)vs ›

$8.41B

1.08

0.93

1.08

1.24

Bruker Corporation (BRKRP)vs ›

$9.35B

0.92

0.82

1.02

1.25

Insulet Corp. (PODD)vs ›

$9.39B

1.83

2.42

2.51

3.28

Henry Schein, Inc. (HSIC)vs ›

$9.60B

0.73

0.77

0.86

0.88

Bruker Corporation (BRKR)vs ›

$9.72B

0.92

0.82

1.02

1.25

Cytokinetics, Incorporated (CYTK)vs ›

$7.80B

6.66

5.35

6.55

8.14

HealthEquity, Inc. (HQY)vs ›

$7.65B

2.99

3.17

3.50

3.09

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The quick ratio (acid-test) for ARWR stock is 5.90.

Is Arrowhead Pharmaceuticals, Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 5.90 is 26% above its 5-year average of 4.69, around the middle of its 5-year range (2.43–8.31).

What is the TTM average quick ratio (acid-test) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The TTM average quick ratio (acid-test) for ARWR stock is 5.05.

What is the 3Y average quick ratio (acid-test) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 3Y average quick ratio (acid-test) for ARWR stock is 5.42.

What is the 5Y average quick ratio (acid-test) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 5Y average quick ratio (acid-test) for ARWR stock is 4.69.

What is the 10Y average quick ratio (acid-test) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 10Y average quick ratio (acid-test) for ARWR stock is 4.71.

What is the 15Y average quick ratio (acid-test) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 15Y average quick ratio (acid-test) for ARWR stock is 4.73.

What is the 20Y average quick ratio (acid-test) for Arrowhead Pharmaceuticals, Inc. (ARWR)?

The 20Y average quick ratio (acid-test) for ARWR stock is 4.86.

DATE	QUICK RATIO (ACID-TEST)
2026-06-30	5.90
2026-03-31	6.23
2025-12-31	3.38
2025-09-30	4.86
2025-06-30	4.87
2025-03-31	5.15
2024-12-31	6.09
2024-09-30	6.74
2024-06-30	4.65
2024-03-31	8.31
2023-12-31	3.73
2023-09-30	3.98
2023-06-30	6.55
2023-03-31	6.60
2022-12-31	4.64
2022-09-30	2.87
2022-06-30	3.32
2022-03-31	2.96
2021-12-31	2.43
2021-09-30	2.59
2021-06-30	2.65
2021-03-31	3.47
2020-12-31	12.62
2020-09-30	7.82
2020-06-30	7.27
2020-03-31	5.84
2019-12-31	6.85
2019-09-30	2.70
2019-06-30	2.76
2019-03-31	2.29
2018-12-31	1.84
2018-09-30	6.27
2018-06-30	8.53
2018-03-31	10.07
2017-12-31	3.82
2017-09-30	3.58
2017-06-30	3.79
2017-03-31	3.23
2016-12-31	2.86
2016-09-30	3.48
2016-06-30	3.34
2016-03-31	4.70
2015-12-31	6.67
2015-09-30	6.47
2015-06-30	12.03
2015-03-31	9.09
2014-12-31	11.11
2014-09-30	13.07
2014-06-30	19.81
2014-03-31	15.45
2013-12-31	8.47
2013-09-30	3.31
2013-06-30	5.15
2013-03-31	0.52
2012-12-31	1.00
2012-09-30	1.23
2012-06-30	1.02
2012-03-31	1.38
2011-12-31	1.81
2011-09-30	3.82
2011-06-30	3.26
2011-03-31	3.44
2010-12-31	1.37
2010-09-30	1.85
2010-06-30	1.90
2010-03-31	1.31
2009-12-31	1.61
2009-09-30	1.06
2009-06-30	0.81
2009-03-31	0.94
2008-12-31	1.86
2008-09-30	2.83
2008-06-30	5.69
2008-03-31	8.96
2007-12-31	11.48
2007-09-30	8.74
2007-06-30	10.92
2007-03-31	19.62
2006-12-31	28.37
2006-09-30	9.85
2006-06-30	18.13
2006-03-31	13.95
2005-12-31	13.40
2005-09-30	22.28
2005-06-30	25.85
2005-03-31	16.75
2004-12-31	20.78
2004-09-30	13.77
2004-06-30	29.32
2004-03-31	299.35
2003-12-31	104.56
2003-09-30	15.74
2003-06-30	0.00
2003-03-31	0.00
2002-12-31	0.00
2002-09-30	0.01

DATE

QUICK RATIO (ACID-TEST)

2026-06-30

5.90

2026-03-31

6.23

2025-12-31

3.38

2025-09-30

4.86

2025-06-30

4.87

2025-03-31

5.15

2024-12-31

6.09

2024-09-30

6.74

2024-06-30

4.65

2024-03-31

8.31

2023-12-31

3.73

2023-09-30

3.98

2023-06-30

6.55

2023-03-31

6.60

2022-12-31

4.64

2022-09-30

2.87

2022-06-30

3.32

2022-03-31

2.96

2021-12-31

2.43

2021-09-30

2.59

2021-06-30

2.65

2021-03-31

3.47

2020-12-31

12.62

2020-09-30

7.82

2020-06-30

7.27

2020-03-31

5.84

2019-12-31

6.85

2019-09-30

2.70

2019-06-30

2.76

2019-03-31

2.29

2018-12-31

1.84

2018-09-30

6.27

2018-06-30

8.53

2018-03-31

10.07

2017-12-31

3.82

2017-09-30

3.58

2017-06-30

3.79

2017-03-31

3.23

2016-12-31

2.86

2016-09-30

3.48

2016-06-30

3.34

2016-03-31

4.70

2015-12-31

6.67

2015-09-30

6.47

2015-06-30

12.03

2015-03-31

9.09

2014-12-31

11.11

2014-09-30

13.07

2014-06-30

19.81

2014-03-31

15.45

2013-12-31

8.47

2013-09-30

3.31

2013-06-30

5.15

2013-03-31

0.52

2012-12-31

1.00

2012-09-30

1.23

2012-06-30

1.02

2012-03-31

1.38

2011-12-31

1.81

2011-09-30

3.82

2011-06-30

3.26

2011-03-31

3.44

2010-12-31

1.37

2010-09-30

1.85

2010-06-30

1.90

2010-03-31

1.31

2009-12-31

1.61

2009-09-30

1.06

2009-06-30

0.81

2009-03-31

0.94

2008-12-31

1.86

2008-09-30

2.83

2008-06-30

5.69

2008-03-31

8.96

2007-12-31

11.48

2007-09-30

8.74

2007-06-30

10.92

2007-03-31

19.62

2006-12-31

28.37

2006-09-30

9.85

2006-06-30

18.13

2006-03-31

13.95

2005-12-31

13.40

2005-09-30

22.28

2005-06-30

25.85

2005-03-31

16.75

2004-12-31

20.78

2004-09-30

13.77

2004-06-30

29.32

2004-03-31

299.35

2003-12-31

104.56

2003-09-30

15.74

2003-06-30

0.00

2003-03-31

0.00

2002-12-31

0.00

2002-09-30

0.01

Quick Ratio (Acid-Test): 5.90

ARWR Quick Ratio

ARWR Average Quick Ratio (Acid-Test) Chart

ARWR Current vs Average Quick Ratio (Acid-Test) Chart

ARWR Quick Ratio (Acid-Test) Metrics

ARWR Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

ARWR Quick Ratio (Acid-Test) History

Related Metrics